ESPR · Esperion Therapeutics Inc

-

Please sign in to comment on ESPR

1 Comment

Admin

3 years, 7 months ago

Esperion Therapeutics, Inc is currently in a long term downtrend where the price is trading 30.8% below its 200 day moving average.

From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.4.

Esperion Therapeutics, Inc's total revenue rose by 881.5% to $10M since the same quarter in the previous year.

Its net income has dropped by 68.7% to $-104M since the same quarter in the previous year.

Finally, its free cash flow fell by 61.9% to $-81M since the same quarter in the previous year.

Based on the above factors, Esperion Therapeutics, Inc gets an overall score of 2/5.

CurrencyCode	USD
Sector	Healthcare
ISIN	US29664W1053
Industry	Drug Manufacturers-Specialty & Generic
Exchange	NASDAQ

Beta	0.25
Market Cap	120M
Dividend Yield	0.0%
Target Price	10.6
PE Ratio	None

ABOUT

Esperion Therapeutics Inc

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

ESPR · Esperion Therapeutics Inc

-

Esperion Therapeutics Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Esperion Therapeutics Inc using a moving average strategy